Focused on early-stage venture creation at the intersection of biotechnology, artificial intelligence, and sustainability.

• Appointed by senior leadership to lead deployment and execution of vastly complex ~$400M global membrane production capacity expansion efforts in service of core bioprocessing & vaccine markets

• Promoted to lead 80+ person organization responsible for over $2B annual revenue product portfolio• Responsible for membrane technologies underpinning multi-billion revenue streams serving bioprocessing, medical, and biomolecular research industries including: mRNA, monoclonal antibody, and viral vector based therapies• Designed and executed ‘unthinkably difficult’ split of central technology organization into two divisions (industrial and life science) to unlock shareholder value, improve operational efficiency, and streamline executive management focus• Created life science-centric vision and rallied 80+ person team through substantial organizational change with 97% retention of team in the context of a change-adverse population and exceptional external job market demand for the team’s talents• Diversity and Inclusion: Achieved world-class diversity (95%) and inclusion (91%) scores for organization in same survey

• Developed multi-year strategic plan for $1.7B membrane technology portfolio spanning all seven business units (from biotech to microelectronics & heavy industries) that focused investment to sustain business and created new lines of growth (e.g., gene therapy, gas separations, vegetable proteins)• Established strategic product planning group to deliver product breakthroughs and bolster core revenue growth; executed six transformative product launches accounting for over $20M in annual revenue• Architected sensors, analytics, and digital solutions growth strategy orthogonal to core business

• Convinced six levels of Pall and Danaher leadership to develop partnership with uniquely enabling pre-revenue company, creating a $20B early market opportunity with a highly differentiated technology• Built & mentored team to expand strategy beyond core materials science competencies into 3D printing and data analytics delivering three product launches within four years that changed the nature of how we competed in a large, mature market

• Selected into and graduated from Danaher General Management Development Program for high potential leaders• Developed multi-year strategic plan for >$1B membrane technology portfolio spanning all six business units (biotechnology, medical, molecular research, industrial, food & beverage, micro-electronics, and aerospace.• Co-led integration of foreign company acquisition, closed prominent technology and product portfolio gap• Established strategic product planning group to deliver product breakthroughs and bolster core revenue growth

Devised and executed business development strategies for advanced, biology inspired material technologies in the purification and process intensification space.Sole business counsel for Harvard President's Innovation Challenge second place awardee AirCrew (now Metal Mark: https://www.metalmark.xyz/)

Identified investment opportunities and conducted diligence on early stage applied science and engineering ventures.

2016 MBA Summer Intern, Technology GroupProvided M&A advisory services to companies evaluating transactions with strategic or financial buyers.

Oasys Water was an early stage company focused on treating world’s most difficult waters. Company received recognition from Bloomberg, World Economic Forum, and Global Water Intelligence for its pioneering technology during my tenure as head of R&D. Acquired by China CAMC Engineering Co., a subsidiary of China National Machinery Industry Corp. (SinoMACH), in 2018.Member of executive management team reporting to CEO. Worked alongside CEO, CFO, VP Engineering, and VP Strategy and Marketing to define and execute company’s strategy. OPERATIONS• Created and managed diverse team of 20+ scientists and engineers, including recruitment and terminations• Responsible for membrane and product development with 20% of total company operations budget• Managed relationship and intellectual property development with strategic partner of critical system component• Developed, designed, sourced, and commissioned key components and sub-systems for first-in-kind desalination process technologyBUSINESS DEVELOPMENT• Built relationships and identified deal opportunities with numerous global technology advocates, strategic commercial partners, and early adopters with focus in Australia, China, India, the Gulf Coast, and United States• Pitched company to >40 world-class strategic and financial investors during Series B fundraising effort• Direct actions while in this role resulted in company’s first unit sales in China and United StatesSTRATEGY• Led development and scaling of synthetic membrane material from laboratory prototype to commercial product• Performed global market, competitive, and valuation analyses to define solution requirements and opportunities• Designed and implemented multi-generational product roadmap for all major system components

• Integral to pre-commercial Series B strategic investment fundraising effort• Regular interfacing with company board of directors – primarily composed of venture capitalists• Developed and managed relationships with strategic partners in the U.S., China, Spain, Japan,Norway, and France, in addition to collaborating with top tier foreign and domestic universities• Principal investigator on federal grants totaling $3.4MM

• Managed two laboratories to support engineering, development, and business development efforts• Achieved 50x cost reduction in key areas of product R&D through vendor and contractor negotiation

Developed, designed, sourced, and commissioned first-in-kind desalination system